Jack O. Egan

2.2k total citations
17 papers, 944 citations indexed

About

Jack O. Egan is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Jack O. Egan has authored 17 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Jack O. Egan's work include Immune Cell Function and Interaction (7 papers), CAR-T cell therapy research (4 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). Jack O. Egan is often cited by papers focused on Immune Cell Function and Interaction (7 papers), CAR-T cell therapy research (4 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). Jack O. Egan collaborates with scholars based in United States. Jack O. Egan's co-authors include Hing C. Wong, Peter R. Rhode, Michael Kalafatis, Kenneth G. Mann, Hongmin Chen, Jen‐Fu Chiu, Xiaoyun Zhu, Wenxin Xu, Kaiping Han and Kevin M. Cawthern and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

Jack O. Egan

16 papers receiving 915 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jack O. Egan United States	12	521	386	169	166	106	17	944
Martin Birkhofer United States	9	371 0.7×	186 0.5×	88 0.5×	140 0.8×	61 0.6×	20	802
Nanette McAtee United States	12	206 0.4×	377 1.0×	241 1.4×	94 0.6×	128 1.2×	16	1.0k
Mitsuhiro Iwahashi Japan	12	449 0.9×	147 0.4×	153 0.9×	238 1.4×	57 0.5×	18	914
Silvia Calpe Netherlands	16	574 1.1×	196 0.5×	180 1.1×	82 0.5×	74 0.7×	27	904
Tetsushi Aita Japan	9	480 0.9×	175 0.5×	168 1.0×	135 0.8×	50 0.5×	15	844
N. Ciobanu United States	13	372 0.7×	285 0.7×	101 0.6×	98 0.6×	61 0.6×	24	672
Amu Therwath France	16	167 0.3×	210 0.5×	257 1.5×	63 0.4×	69 0.7×	39	745
Britta Maecker Germany	16	525 1.0×	398 1.0×	204 1.2×	146 0.9×	72 0.7×	22	875
Kazuyuki Yamaguchi Japan	15	367 0.7×	146 0.4×	158 0.9×	271 1.6×	51 0.5×	52	844
Katalin Pálóczi Hungary	14	238 0.5×	119 0.3×	125 0.7×	187 1.1×	56 0.5×	67	592

Countries citing papers authored by Jack O. Egan

Since Specialization

Citations

This map shows the geographic impact of Jack O. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack O. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack O. Egan more than expected).

Fields of papers citing papers by Jack O. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack O. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack O. Egan. The network helps show where Jack O. Egan may publish in the future.

Co-authorship network of co-authors of Jack O. Egan

This figure shows the co-authorship network connecting the top 25 collaborators of Jack O. Egan. A scholar is included among the top collaborators of Jack O. Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack O. Egan. Jack O. Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhu, Xiaoyun, Qiongzhen Li, Niraj Shrestha, et al.. (2023). A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. Frontiers in Immunology. 14. 1114802–1114802. 6 indexed citations

Geller, Melissa A., Manish R. Patel, Hing C. Wong, et al.. (2023). 767 Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumors. SHILAP Revista de lepidopterología. A862–A862.

Chaturvedi, Pallavi, Niraj Shrestha, Meng Wang, et al.. (2022). Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells. Molecular Therapy. 30(3). 1171–1187. 21 indexed citations

Geller, Melissa A., Manish R. Patel, Hing C. Wong, et al.. (2022). 724 A phase I study of HCW9218, a bifunctional TGF-β Antagonist/IL-15 protein complex, in advanced solid tumors. Regular and Young Investigator Award Abstracts. A757–A757. 1 indexed citations

Margolin, Kim, Chihiro Morishima, Vamsidhar Velcheti, et al.. (2018). Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(22). 5552–5561. 146 indexed citations

Fehniger, Todd A., Brian Hess, Veronika Bachanová, et al.. (2018). Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). Cancer Research. 78(13_Supplement). CT146–CT146. 6 indexed citations

Ellis, Amy, Alexis J. Balgeman, Gabrielle L. Barry, et al.. (2017). ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment. Journal of Virology. 92(3). 47 indexed citations

Rhode, Peter R., Jack O. Egan, Wenxin Xu, et al.. (2015). Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunology Research. 4(1). 49–60. 170 indexed citations

Gomes-Giacoia, Evan, Makito Miyake, Steve Goodison, et al.. (2014). Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion. PLoS ONE. 9(6). e96705–e96705. 78 indexed citations

10.

Xu, Wenxin, Jack O. Egan, Bai Liu, et al.. (2014). Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells. Journal for ImmunoTherapy of Cancer. 2(Suppl 3). P123–P123. 1 indexed citations

11.

Zhu, Xiaoyun, Warren D. Marcus, Wenxin Xu, et al.. (2009). Novel Human Interleukin-15 Agonists. The Journal of Immunology. 183(6). 3598–3607. 123 indexed citations

12.

Jiao, Jin‐an, Andrew B. Kelly, Ulla M. Marzec, et al.. (2009). Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site. Thrombosis and Haemostasis. 103(1). 224–233. 21 indexed citations

13.

Welty‐Wolf, Karen E., Martha Sue Carraway, Thomas L. Ortel, et al.. (2005). Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. American Journal of Physiology-Lung Cellular and Molecular Physiology. 290(1). L21–L31. 65 indexed citations

14.

Egan, Jack O., Michael Kalafatis, & Kenneth G. Mann. (1997). The effect of Arg³⁰⁶ → Ala and Arg⁵⁰⁶ → Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Science. 6(9). 2016–2027. 38 indexed citations

15.

Chen, Hongmin, Jack O. Egan, & Jen‐Fu Chiu. (1997). Regulation and Activities of α-Fetoprotein. Critical Reviews in Eukaryotic Gene Expression. 7(1-2). 11–41. 95 indexed citations

16.

Kalafatis, Michael, et al.. (1997). The Regulation of Clotting Factors. Critical Reviews in Eukaryotic Gene Expression. 7(3). 241–280. 107 indexed citations

17.

Zhang, Xiao-kun, et al.. (1992). Hepatitis B virus DNA integration and expression of an erb B-like gene in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 188(1). 344–351. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact